Method of preparing morphine derivatives

专利摘要:
Novel derivatives of morphine having the general formula: <IMAGE> (1) wherein R2, R3, R4, R5 and R6 are certain specified values, and their pharmaceutically acceptable salts. The compounds exhibit activity in the central nervous system and may be presented in the form of pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.
公开号:SU856381A3
申请号:SU782595495
申请日:1978-03-21
公开日:1981-08-15
发明作者:Юрек Кобылески Рышард；Вильям Льюис Джон；Вильям Кирби Гордон
申请人:Рекитт энд Колман Продактс Лимитед；
IPC主号:

专利说明:

This invention relates to a method for producing morphine derivatives not described in the literature of the general formula: where Rl is methyl or arylalkyl is hydrogen, alkyl, alkenyl C-Cfr, cycloalkyl C-C7-alkyl, arylalkyl or arylalkenyl Cj-Cg provided that R does not contain structural group - СНаСН-, attached to the nitrogen atom in position 14; alkyl Cr-C3 or a group co, where hydrogen, alkyl, alkenyl, aryl, arylalkyl, ari alkenyl C a-C 5-, cycloalkyl Cj-Cg or cyclopropylmethyl or by the alkoxy group “is hydrogen; R is hydroxyl or "together represent an oxygen atom; a broken line means a possible carbon-carbon bond with pharmacological activity. A method of producing alcohols is known, which consists in dimethylation of methyl ethers under the action of boron tribromide Cl. . The purpose of the invention is the synthesis of new pharmacologically active morphine derivatives of general form. Step 1, based on the use of a known reaction. This goal is achieved by the fact that according to the method for producing morphine derivatives of general formula T, the compound of general formula is rfHjO 1G-B. . J where R to R are as indicated, is treated with borobribromide at a temperature of from -50 to in a chlorinated aliphatic hydrocarbon medium, followed by isolation of the desired product. Methylene chloride is preferably used as the chlorinated hydrocarbon. The process is preferably carried out at a temperature of from -30 to -10 ° C. Morphine derivatives of general formula 1 can be used in clinical practice as analgesics, neuroleptic analgesics, and as protivopolozhnyh drugs. Example 1. 14-U-Aminocodeinone. 800 mg of dimethyl ketal 14-P1-nitrocodeinone are dissolved in 100 ml of hot absolute methyl alcohol, and the solution is treated with 1.25 g of ammonium chloride and 1.25 g of zinc powder. The mixture is heated under reflux for 1.5 hours. The reaction mixture is filtered and the filtrate is evaporated in vacuo. The residue obtained is dissolved in chloroform and passed through a column of alumina grade c. The column was washed with chloroform and the combined eluents were evaporated in vacuo. The residue is recrystallized from aqueous methyl alcohol to give Dimethyl 14-p-aminocodeinone as colorless needle crystals (0.58 79%), melting point 133-134 ° C. The solution of ketal in dilute hydrochloric acid is held at room temperature for 2 the pH is adjusted to 7 by addition of sodium bicarbonate and extracted with chloroform. The combined extracts are dried, the solvent is removed in vacuo, prepared from boiling tT04Ka petroleum ether 80-100 ° C) 14-p) -aminocodeinone as colorless needle crystals, point melting neither 193-19 4 ° C. Example 2. 14-1b-Methylamino. codeine and A solution of 2.6 dimethyl ketal 14-1-aminocodeinone in 100 ml of chloroform is treated with 5 g of sodium bicarbonate and 50 ml of water. -0.9 g of ethyl chloroformate were added dropwise to the stirred mixture, and the mixture was further stirred at room temperature for 30 minutes. The organic layer is separated, and the aqueous phase is extracted with chloroform. The combined extracts are dried and evaporated in vacuo. The residual oily substance is adsorbed onto grade alumina and eluted with chloroform. The combined eluents are evaporated in vacuo. The residue was dissolved in anhydrous tetrahydrofuran (15 ml) and added dropwise to a stirred suspension of lithium aluminum hydride (1.0 g in 40 ml of tetrahydrofuran. The resulting mixture was stirred at room temperature for 30 minutes and heated under reflux for a further 30 minutes. over 2 hours. The excess lithium aluminum hydride is decomposed with a saturated solution of sodium sulfate, the suspension is filtered and the solid is washed with chloroform. The combined filtrates are washed with water, dried and evaporated in vacuo. The remaining oil is dissolved in an excess of dilute hydrochloric acid and incubated at room temperature for 2 hours, the pH is adjusted to 7.0 with sodium bicarbonate and the mixture is extracted with chloroform. The extracts are combined, washed with water, dried and evaporated. The residue is recrystallized from sulfuric ether - petroleum ether to give 14- | L-aminocodeinone as colorless crystals (0.90-g, 38%) with a melting point of 157-158c. B) A solution of 3.0 g of dimethyl ketal of 14-p-aminocodeinone in 100 ml of 10% aqueous acetone is treated with 5, 0 g sodium bicarbonate, 2.38 g methyl iodide and boil for 3.5 hours. The acetone is evaporated in vacuo, statok dissolved in dilute hydrochloric acid and kept at room temperature for 2 hours. The solution was filtered, additives sodium bicarbonate adjusted to pH 7.0 and extracted with methylene chloride and the organic extracts proglyvayut water, dried and evaporated. The target material was isolated from the mixture of products by chromatography on silica gel (chloroform + 10% methyl alcohol); Obtain 0.51 g of colorless needle-shaped crystals of 14-b-methylamino-co-dinone by recrystallization from petroleum ether (with a ripening point of 60-80 ° C). Melting point 158-159 ° C. Example 3. 14-f-ethylamine-cocoinone. A solution of dimethyl ketal 14-p) -aminocodeinone (4.0 g) in 20 ml of dry pyridine is cooled to, treated with b ml of acetyl chloride and the mixture is left to cool to room temperature for 1 hour. The volatile components are removed in an acum and the residue is extracted with a mixture chloroform and dilute caustic soda solution. The organic extracts are separated, dried and evaporated to give an oily product, which is passed through a short column of alumina of the I grade using chloroform as an eluent solvent. The eluents are evaporated and a foam is obtained. This foam was dissolved in dry tetrahydrofuran (50 ml) and added dropwise over a period of 5 minutes to a suspension of 2.0 g of lithium aluminum hydride in dry tetrahydrofuran (30 ml). The mixture is heated under reflux for 2 hours. To decompose excess lithium aluminum hydride to a cooled reaction
passed through a short column of alumina grade. The eluents of a pale yellow color, yiary, give a yellow oil that crystallizes upon trituration with sulfuric ether. The resulting crystals are filtered, washed with ether and recrystallized from a mixture of acetone and petroleum ether (60-80 ° C). Colorless needles (3.89 g) are obtained with a melting point of 171172, 5 ° C.
Example 14. 14-p-15-phenylpent-4-enyl) aminocodeinone.
. a) A solution of 5 g of 5-phenylpent-4-enoic acid in chloroform is treated with 6.3 g of triethylamine, cooled to -30 ° C, treated with 4.27 g of isobutyl chloroformate and the resulting solution is stirred at -20 ° C for 5 min The solution is then treated with a solution of 10.8 g of dimethylkettsh 14-p-aminocodeinone in chloroform (50 ml) and the solution is allowed to warm to room temperature over 1 hour. The solution is shaken with water (twice), the chloroform layer is separated, dried and evaporated a yellow oily product is obtained. The latter is crystallized by rubbing with petroleum ether. The solid product is collected and dried.
b) The specified substance is reduced by the method described in example 4.
Example 15. 14-p-pentanoyl-aminocodeinone.
A solution of dimethyl 14-1'-aminocodeinone (5.0 g) in chloroform (100 ml) and triethylamine (5 ml) is cooled to, treated with pentanoyl chloride (1.9 g) and allowed to warm to room temperature over 1 hour. The solution is washed with water, evaporated to low volume, dissolved in tetrahydrofuran (50 ml), treated with 50 ml of 2N SALTIC acid and incubated for 2 hours. The mixture is neutralized, extracted with chloroform, the extracts are dried, evaporated and evaporated to give a colorless solid which is recrystallized from a mixture EtOH and diisopropyl ether to give the product as colorless plates, m.p. 213-217 ° C.
Example 16. 14-P-para-oxycinnamoyl-aminocodeinone.
A solution of 3 g of dimethyl ketal of 14- | 1-aminocodeinone in 60 ml of chloroform and 3 ml of triethylamine is treated with para-acetoxycinnamoyl chloride (freshly prepared from 1.68 g of acid and thionyl chloride) and stirred with BcUOT at room temperature for 2 hours. The solvent is evaporated and the oil is evaporated dissolved in concentrated hydrochloric acid.
The solution is held on a steam bath for 10 minutes. The solution is diluted with water, neutralized with acidic sodium carbonate, extracted with a mixture of methyl alcohol and chloroform (1: 1), and the combined extracts are dried and evaporated. The resulting bright yellow solid is recrystallized from methyl alcohol, to obtain the target product (1.61 g) in the form of bright yellow needle-like crystals with
0: melting point: 316-317 ° C.
Example 17. (Pent-2-enoyl) aminocodeinone.
The desired product is obtained from pent-2-enoic acid and 14-b-aminocode5 n dimethyl ketal, following the procedure described in example 14a, and the corresponding codeine is hydrolyzed according to the general method for acid hydrolysis described in example 15. The product subjected to
0 recrystallization from aqueous ethyl alcohol, has a melting point of 224-22 ° C.
Example 18. 14- (A-dimethylamicocodeinone.
five
a) Following the procedure of Example 5, a solution of dimethyl ketal 14-p-amino (s-benzyloxycarbonyl) norkodeinone in acetone is alkylated with acetone with an excess of methyl iodide. After 36 hours the mixture is diluted
0 with water, extracted with chloroform, the extracts are washed, dried and evaporated. The resulting pale yellow oily product is crystallized by trituration with ether and the resulting dimethyl 5 tal 14-P-dimethylamine (4-benzyloxycarbonyl) norcodeinone is used without further purification.
b) Following the procedure of example 3, this substance is alumi- num reduced. The lithium RIDOM, and then acid hydrolysis, following the same general procedure, is obtained from cyclohexane 14-b-dimethylamine-rhodeinone in the form of plate crystals with a melting point of 205-207.7 ° C.
five
Example 19. 14-L-hexanoyl-amino- (N-benyl) norroquinone.
a) Acrylate the dimethyl ketal solution with 14- (S-amino-(N-benzyloxycarbonyl) norkodeinone hexo-sanoyl chloride) in chloroform / triethylamine solution by heating to reflux for 24 hours. The reaction mixture is washed with water, dried and evaporated, get
5 red oily product. The mixture is purified by chromatography on silica gel, and dimethyl ketal, 14-P-hexanoyl-ammonium- {M-benzyloxycarbonyl) -norkodeinone is hydrolyzed with aqueous acid in
In tetrahydrofuran solution, the corresponding co.ceinone is obtained as a colorless oil.
b) A solution of this substance in ethyl acetate / acetic acid (5: 1) is hydrogenated in 5
48 h over 10% palladium on coal. The solvent is removed, the mixture is neutralized, extracted with chloroform, the extracts are dried and evaporated /, a colorless oil is obtained, which is crystallized by rubbing with ether. A colorless solid is obtained, which is used without further purification.
c) Following the procedure of example 5, the solution of 14-P-hexanoyl-aminoronicodeinone is scinned with benzyl bromide, and obtained from ethyl alcohol needle-shaped. crystals of 14-1b-hexanoylamino (N-benzyl} norcodeinone with a melting point
206-210 ° C.
Example 20. 14- (L-hexanoylamino-N- (2-phenethyl) norcodeinone.
The target product is synthesized analogously to example 19 in the form of lamellar crystals from aqueous ethyl alcohol, melting point 1b3-1b6C.
Table 1 shows other compounds of formula
15 synthesized by the methods described in the examples.
Table 1
H N
H-CO, HT
N-SdNd
H
H-CjH i
N N N N N
ns (,
nC | 0H2
IZO-S Nd
CHqPh

(CHQ) Ph
H N
(CH, j) 2, Ph
tOCg-H
H
COCfcH ri
H
coCaHjg
H 23
H
CoPh
H
Co (SNg) o.RN
H
H
H
n-sen
H
CH-with-CH,
H
CH, -c-CgH 5
H
CH, CH, j -c-C3H5
H
{WITH)
H
(CH) sP
B / R
137-138
about 141-144
R about 122-122,5
R o
E / R 137-139.5 about 72-76
R o
A / M / E
191-195 about 177-181
R o
H 163.5-165 o
P 194-197 about
P 124-125 about
A / I PE 209.5-212 o
E / R 175-178 about
A / IPE 174-177.5 o
A / IPE 157-158 about
A / IPE 152-155 o
E / R 190-191 about
P 107-107,5 about 164-167
M / E o
Et / W 125-126 about
Р / А 132-133 о
P 151-152 about
R
96-98 about

М / А / Е 237-237,5 о
the mixture is added dropwise with a saturated aqueous solution of sodium sulfate and the precipitated altaminium salts are removed by filtration, thoroughly taken up in chloroform. The organic extracts are washed with water, dried and evaporated. The resulting oily product is diluted with dilute hydrochloric acid, held at room temperature for 2 hours, adjusted to pH 0 with sodium bicarbonate, and the mixture is extracted with chloroform. The combined extracts are washed with water, dried and evaporated, to give an oily substance, which is passed through a short column with grade III alumina in chloroform. The eluents were evaporated, and 1.59 g (41.8%; 14-| -ethylamino-co-dinone in the form of colorless needle-like crystals, melting point 22b, 5-228 ° C, are obtained from petroleum ether (60-80 ° C)).
Example 4. 14- (b-Octylamino-codeinone.
A solution of 5.0 g of dimethyl ketal of 14- / -amino-co-dinone in 100 ml of chloroform and 5 MP of triethylamine is cooled before being treated with octanoyl chloride (2, Ь g and the reaction mixture is allowed to take room temperature for 1 hour. The solvent is then evaporated to dissolve the product in ether the salts are filtered off and the ether is removed in vacuo to give a colorless crystalline product, recrystallization of which from petroleum ether (with a boiling point of 40-60 ° C) yields colorless crystals of dimethyl ketal of 14-P-octanoyl aminocodeine with a melting point of 89-90.5 ° C . The substance is added in portions over 5 minutes to a cooled suspension of lithium apium hydride (2.5 g in 1 ml of dry tetrahydrofuran and allow the mixture to warm to room temperature and then stirred at room temperature for 8 hours. Excess lithium aluminum hydride is decomposed by adding drop by drop of saturated TacoPia sodium sulfate, the aluminum salts are filtered, washed thoroughly with chloroform and the organic extracts are washed with water and dried. The solvent is evaporated in vacuo. The residual oily product was dissolved in a mixture of chloroform (50 ml) and dilute hydrochloric acid (65 mp and kept at room temperature for 2 hours, the pH was adjusted to 7.0 by the addition of sodium bicarbonate and the mixture was extracted with chloroform. The combined extracts were washed with water. , dried and the solvent is removed in vacuo.The residual oil is passed through a short column with alumiutfi oxide.
using as
neither sort
chloroform and the eluents are evaporated in vacuo. This product is not obtained in crystalline form, it is converted into the hydrochloride by adding a solution of dry NSA in sulfuric ester and recrystallized from a mixture of acetone (methyl alcohol) sulfuric ether, 14-p-octylamino-co-hydrochloride (1.83 g) is obtained as pale yellow crystals with a melting point of 164-167 ° C. Try it on. 14-p-cyclopropylmethylaminocodeinone.
a) A solution of 3.0 g dimethylketal
0 14-p | -amino-codeine in 10% aqueous acetone (50 ml is treated with 10 g of potassium iodide, up to g of sodium bicarbonate, boiled under reflux, treated with 1.0 g of cyclopropyl methyl bromide and heated under reflux for 5 The acetone was removed in vacuo, the residue was diluted with water, extracted with chloroform, the combined extracts were dried and evaporated to give an oily product.
The product is dissolved in dilute hydrochloric acid and kept at room temperature for 2 hours. The pH is adjusted to 7 with O with sodium bicarbonate, the mixture is extracted.
5 chloroform and the combined extracts are dried and evaporated. The resulting oily product is adsorbed onto the basic agaomini oxide of grade 1, eluted with chloroform, and isolated by recrystallization from petroleum ether (60-80 ° C) 14- | L-cyclopropylmethylamine-codelenone (1.78 g, 58%) as a weakly polar component with a melting point of 148-150 ° C.
five
b) Reduction of dimethyl ketal 14- (L-cyclopropylcarbonylaminocodeinone (prepared in accordance with the general method of Example .3) using lithium aluminum hydride followed by whale slot hydrolysis using
The same general procedure also allows the preparation of 14- (L-cyclopropyl methyl aminocodeinone.
Example 6. 14 -) - formylamino5 codeinon.
A solution of 2.0 g of 14-P-aminocodein-dimethyl ketal in 10 ml of 95% formic acid is kept under stirring at 55 ° C for 6 hours. The cooled reaction mixture is poured into excess sodium bicarbonate and extraheated with methylene chloride. The combined extracts are washed with water, dried, the solvent is evaporated in
5 vacuum to give an oily product, which is extracted on alumina grade HI and eluted with chloroform. The eluents are evaporated in 1eakum, the resulting solid is recrystallized from dichloromethane petroleum ether VC boiling point 60-80 °), poluchigot 1.39 g of 14- (L-formylamino-codelenone (73.5%) in the form of colorless needle-shaped crystals with a melting point 255- 256 0. Example 7. 14-Acetylamino codeine. To a solution of 0.164 g of 14-G8-aminocodeinone in dry pyridine (2 ml), add 1 ml of acetic anhydride and hold the mixture at room temperature for 12 hours. The volatile components were removed. under vacuum, the residue is diluted with an excess of sodium bicarbonate solution. and extracted with chloroform.The combined extracts are dried and evaporated in vacuo and the resulting solid residue is recrystallized from methyl alcohol to give 0.174 g (94%) of colorless 14-p-acetylamino-co-dinone needle-like crystals with a melting point of 257-258c. Example 8, 14-p- Butyrylaminocodeinone. A solution of 4.0 g of 14 - (- - aminocodeinone dimethyl ketal in 20 ml of pyridine is cooled to 0 ° C, treated with butyryl chloride (6 ml) and the mixture allowed to return to room temperature for 1 hour. The volatile components are removed in vacuo, the residue is dissolved in a mixture of 50 ml of chloroform and 50 ml of dilute acid, the solution is kept for 8 hours. The pH is adjusted to 7.0 by the addition of sodium bicarbonate and the mixture is extracted with chloroform. The combined extracts are washed with water, dried and the solvent is removed in vacuo. OAT is passed through a short column with 1M aluminum oxide and the eluent is evaporated. The residual solid product is recrystallized from petroleum ether (with a boiling point of 60-80 ° C), to obtain 0.58th colorless crystalline 14- | L-butyr ylaminocodeinone with a melting point of 229231. C. Pr and measures 9. 14- (5-cinnamoyl-aminocodeinone. A solution of 2.0 g of dimethyl ketal of 14-p-aminocodeinone in 100 ml of chloroform is first treated with a solution of 10 g of sodium bicarbonate in 100 ml of water and then cinnamic acid chloride (from 5 g of cinnamic acid acid) and the mixture is stirred for 8 hours at room temperature. The organic layer is separated, treated with concentrated hydrochloric acid and maintained at room temperature for 2 hours. The mixture is alkalinized with a dilute sodium hydroxide solution and dried at room temperature for 30 m. The organic layer is separated, dried and evaporated in vacuo. The residue is chromatographed on alumina of 1-grade alumina using chloroform as solvent and 1.85 g (75%) of 14-Pi-cinnamyl-aminocodeinone are obtained as colorless after recrystallization from methyl alcohol. tablets with a melting point of 273-2750 ° C. Example 10. 14-p-amino-7,8-dihydrocodein dimethyl ketal. A solution of 14-E-amino-co-din-dimethyl ketal (4 g) in dry methyl alcohol fSOO ml) is hydrogenated at atmospheric pressure over 10% palladium on coal (1 g). After the absorption of H / j ceases, the catalyst is removed by filtration and the solvent is evaporated in vacuo, an oily product is obtained, which is dissolved in methylene chloride and passed through a short column of aluminum oxide of grade 1 (1. The eluents are evaporated in vacuo. The residual oil is subjected to crystallization when pentane is added, the solid product is recrystallized from pentane; 14-p -amino-7, 8-dihydrocodeinone crystalline solid dimethyl ketal is obtained (3.2 g, 79.6%) with a melting point of 89-90.5 ° C. Example 11. 14-p-acetylamino-7, 8-dihydrocode The target product is synthesized from dimethylketal of 14-p-amino-7,8-dihydrocodeinone, following the general method of example 8. The resulting product is recrystallized from a mixture of diethyl ether and petroleum ether. 14-P-acetylamino-7,8 crystals are colorless, needle-shaped. α-dihydrocodeinone with a melting point of 198-199.5 ° C. Example 12. 14-p-aminocodein A solution of 14-p-aminocodeinone in methyl alcohol is treated with portions of lithium borohydride at room temperature. After removal of the solvent from the cooled reaction mixture, 14-p-aminocodein is obtained, the melting point of which is 185-186 ° C. Example 13. 14- | l-allylamino-code. V, Following the method of example 5, alkylate the solution of dimethylketal 14-p-amiHO-iN-benzyloxycarbonyl) -norkodeinone with allyl iodide. The obtained intermediate product is used in accordance with the procedure described below without further purification. A solution of 13.0 g of the indicated intermediate in tetrahydrofuran (50 ml) is added dropwise over 5 minutes to an ice-cooled, stirred suspension of lithium aluminum hydride (6.5 g) in 100 ml of tetrahydrofuran and the resulting mixture is stirred at room temperature for 24 h. Excess lithium aluminum hydride is decomposed by careful addition of saturated sodium sulfate solution, aluminum salts are filtered, washed thoroughly with chloroform, and the combined filtrates are evaporated to a small volume. The resulting oil is acidified with 2N. hydrochloric acid (50 ml) I and incubated for 2 hours. The mixture is neutralized, extracted with chloroform, the extracts are washed, dried and evaporated, an oil is obtained, which is
17
SOSbN, 4
H
n
SOSDN
H
Sosin s
n
18
856381 Continuation of the table. 2
A / r
153-155
about a / p 198-202
ABOUT
A / r
141-143
o A / R 109-110 o
.19. (4-Me) COCHQPh CO (CH ,, CO (CH,) 4.Ph eo (CHjjyph, COCH CHSSH (CH) ,; CO (CH2), COCH CHCH2 CH) CO (CH) SP SKSNO, COCHfj CH CHPh CO (CHrL) rj, O139-141 COCH CH-SbN4 (4-CE; O302-304 COCH CH-SbH4 (4-Me) O274-276 COCH CH-SbH4 (4-OH) O240-242, -C H4 { 4-Cl) O277-279 COCH2CH-Cf, H4 (4-Me; O143-145 COCHjCH-C jH t -OH) o 260-261 COCH CH-CjH (3.4-ce; o 195-197
used in recrystallization
 Solvent, Dichlorohydrate. Hydrochloride.
856381
20 Continued

权利要求:
Claims (3)
[1]
tab. 2 O250-252 O166-168 O270-272 O231-233 O200-202 O1 / 6-177 O267-269 O285-286 O148-150 O131-133 O225-227 O117-119 O134-139 E / P Et / W Et / W Et Et CH Е / Р Е / Р Е / Р Е / Р Е / Г Е / Р Et / W Е / Р Et / W Et / W В / М Et / W Et / W 5 В / М Е / Р The solvent used for ne-, 8 dihydro. Example 21: 14-p-aminomorphia) to a stirred solution of dimethyl ketal 14-1B-aminocodeinone in 60 MP of methylene chloride at-78 ° C is added dropwise 3.0 ml of borobromide, after 5 min with the reaction mixture heated to -15 ° C and maintain the temperature equal to 1h. The reaction mixture is diluted with 10 ml of methyl alcohol and the solution is poured into the excess. Continue the table, 1 crystallize the caustic sulphurum at 0 ° C. The organic layer is separated, washed with caustic soda and decanted. The combined aqueous solutions are acidified with dilute hydrochloric acid, adjusted to pH 7.0 with sodium bicarbonate, and extracted with an aqueous solution of chloroform. The combined extracts are dried and evaporated to give a tan solid (1.25 g), which is recrystallized from chloroform / petroleum ether, to obtain 14-p-amino morphinone colorless needle crystals with melting point above b) Cool to 14-fi solution -nitrocodeinone or the corresponding dimethylketal in methylene chloride, treated with borobromide and stirred at minus 20 - minus for 1 h. The reaction mixture is treated with methyl alcohol and poured into a dilute caustic soda solution. The carbon dioxide gas is passed through it, and then extracted with methylene chloride. Evaporation of the extracts gives an orange-yellow gum, during recrystallization of which from sulfuric ether / petroleum ether, pale yellow needle-like crystals are obtained, the melting point of which is 200 ° C (with decomposition). c) Treat the solution of 14-p-nitromorphinone in methyl alcohol with a water suspension of sodium dithionite (excess) and the resulting mixture is carefully boiled under reflux for 8 hours after removing the solvent, the residue is extracted and the extracts are evaporated, 14- (b β-aminophorinone. Example 22. 14-L-methylaminoforminone. A solution of 0.7 g of 1-1-1B-methylaminocode inon in 60 ml of methylene chloride is cooled to, treated with 2.5 ml of borobromide and then stirred for 2 hours at minus 20 minus 30 ° C. The reaction mixture is diluted with methyl alcohol (10 ml), in poured into dilute sodium hydroxide solution, taken in sufficient quantity to give it basicity, stirred for 5 minutes, acidified with condensed hydrochloric acid and adjusted to pH 7.0 by addition of sodium bicarbonate. the organic extracts were dried with a mixture of chloroform and methyl alcohol (3: 1), and then the solvent was removed in vacuo. The resulting solid was purified on a short column of 111-grade aluminum oxide, using a mixture of methyl sulphate as eluting solvent Irta and chloroform (1: 5). The eluents are evaporated, and 0.29 g (44%) of pale yellow needle-like crystals of 14-b-methylaminomorphinone with a melting point of 250-252 ° C with decomposition are obtained from the solid residue after recrystallization from chloroform-petroleum ether. Example 23. 14-p-pentamino-7,8-dihydromorphinone. A solution of 1.5 g of 14-p-pentanoylaminomorphinone in methyl alcohol (60 ml) is hydrogenated at atmospheric pressure over 10% palladium on carbon (300 mg). After termination of the hydrogen uptake, the catalyst is filtered off, the residual oil is dissolved in ether, treated with a saturated solution of hydrochloric acid in ether, the resulting hydrochloride is separated by filtration, and crystallized from methyl alcohol: ether to give a colorless crystalline substance (1.03 g) with a melting point 199-200 C. Example 24. 14-p) -hexanoylamino- (N-benzyl) normorphinone. Following the procedure of Example 22, the corresponding codeine is dealkylated and a colorless powder with a melting point of 108-110 ° C (glassy mass) is obtained by recrystallization from ether-petroleum ether. Example 25. 14-f-hexanoyl-amino-N- (2-phenethyl) normorphinone. Following the procedure of Example 22, the corresponding codeine is dealkylated and a colorless powder is obtained by recrystallization from ether-petroleum ether. Melting point is 94-9 bps (vitreous flame). Table 2 describes the preparation of other compounds of the formula prepared under the conditions of Example 22. Table 2 Table 2 and Table 2 and 2 have the following meanings: A — acetone; DMS-dichloromethane P - petroleum ether; PE - diieopropyl ether; C is chloroform; E - ester W - water; H is hexane; CH is cyclohex-; san; Et is alcohol; M is methanol; B - butanol; d - decomposition. The invention of the method of producing morphine derivatives of the form I where I R is methyl or arylalkyl hydrogen, alkyl, orC, alkenyl, cycloalkyl CJ-CT. alkyl (h, arylalkyl, sfilalkenyl, provided that R does not contain a structural group attached to the nitrogen atom at position 14; alkyl or COR group, where fC is hydrogen, alkyl, alkenyl Crj-Cj, aryl, arylalkyl, arylglylenyl C / j -Cfl, cycloalkyl or cyclopropylmethyl, wherein aryl is phenyl, unsubstituted or substituted by chlorine, alkyl, hydroxyl or alkoxy group hydrogen; R is hydroxyl or; R and R together represent an oxygen atom, a broken line means a possible carbon-carbon bond, characterized in that the compound of formula II, s where R-R6 have the indicated meanings, is treated with boribribromide at a temperature of from -50 to chlorine-rich hydrochloride. with the subsequent allocation of the target products.
[2]
2. Method POP1, characterized in that methylene chloride is used as the chlorinated hydrocarbon.
[3]
3. Method POP1, characterized in that the process is carried out at a temperature of from -30 to. Sources of information taken into account in the examination 1. Fizer L., Fizer M. Reagents for organic synthesis. M., 1970, Vol.1, p.110.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US4423044A|1983-12-27|3,4-Dihydro-5H-2,3-benzodiazepine derivatives and pharmaceutical use thereof

---

US3026325A|1962-03-20|5-hydroxy-alpha-alkyltryptophans

---

EP0200859A1|1986-11-12|Steroidal 5-alpha-reductase inhibitors, processes for their preparation and pharmaceutical compositions containing them

---

SU856381A3|1981-08-15|Method of preparing morphine derivatives

---

EP0005889A1|1979-12-12|Process for the preparation of beta-lactam derivatives, the novel derivatives so obtainable and pharmaceutical compositions containing them

---

US3705907A|1972-12-12|4-|-3-aminopropoxy)-indole derivatives

---

US4145427A|1979-03-20|N- 1-|-4-piperidyl!-sulfonic acid amides and salts thereof

---

Alcaraz et al.1994|Asymmetric syntheses of 1-amino-2-phenyl | cyclopropanecarboxylic acids by diastereoselective cyclopropanation of highly functionalized monochiral olefines

---

US3976641A|1976-08-24|Cephalosporin intermediates and process therefor

---

US4094987A|1978-06-13|2-|-ethanols

---

EP0019440A1|1980-11-26|Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them

---

US4235921A|1980-11-25|Treating muscular spasms and convulsions with 3-azabicyclo[3.1.0]hexanes

---

US4181740A|1980-01-01|Indolyl acetic acid derivative

---

IE50006B1|1986-01-22|Derivatives of tetrahydropyrid-4-yl-indole

---

US2944064A|1960-07-05|Process for preparing 5-hydroxy-tryptamine through new intermediates

---

GB2212153A|1989-07-19|Phenyl hydroxamic acids

---

US4835175A|1989-05-30|Indole derivatives pharmaceutical preparations based thereon, and β-receptor stimulation therewith

---

CS203993B2|1981-03-31|Method of producing 2,9-dioxatricyclo /4,3,1,oup 3,7/dececanes

---

US4330555A|1982-05-18|Indanyloxamic derivatives, their preparation and pharmaceutical compositions containing them

---

US4123545A|1978-10-31|N-Propyl-3|-3-|-pyrrolidine

---

US3429884A|1969-02-25|Novel quinolizidine derivatives or salts thereof and process for preparing the same

---

US3932426A|1976-01-13|3-[1-Hydroxy-2-|ethyl]-5-phenylisoxazole

---

US3598860A|1971-08-10|2 - |-phenoxy) lower aliphatic monocarbocyclic acids and esters thereof

---

US3898215A|1975-08-05|Rescinnamine-like compounds and a process for producing the same

---

PL138052B1|1986-08-30|Method of obtaining novel 4-/2-hydroxy-4-/substituted/phenyl/naphtene-/1h/-ones-2 and their derivatives

同族专利:

---

公开号 | 公开日

---

PL111722B1|1980-09-30|

---

AT360664B|1981-01-26|

---

IT1105172B|1985-10-28|

---

DK149753B|1986-09-22|

---

GB1587831A|1981-04-08|

---

CS199522B2|1980-07-31|

---

US4241067A|1980-12-23|

---

SE436132B|1984-11-12|

---

ZA781525B|1979-04-25|

---

AU518614B2|1981-10-08|

---

LU79295A1|1979-10-29|

---

HU177722B|1981-12-28|

---

DD135081A5|1979-04-11|

---

IE46442B1|1983-06-15|

---

DE2812581A1|1978-09-28|

---

CA1089455A|1980-11-11|

---

AU3435678A|1979-09-27|

---

FR2384775B1|1981-04-30|

---

IT7848545D0|1978-03-22|

---

BE865182A|1978-09-22|

---

ATA204378A|1980-06-15|

---

CH630629A5|1982-06-30|

---

DK149753C|1987-07-06|

---

FR2384775A1|1978-10-20|

---

AR218296A1|1980-05-30|

---

SE7803329L|1978-09-24|

---

JPS53121798A|1978-10-24|

---

IE780514L|1978-09-23|

---

NL7803084A|1978-09-26|

---

ES468170A1|1979-01-01|

---

JPS6259112B2|1987-12-09|

---

NZ186693A|1979-10-25|

---

DK129978A|1978-09-24|

---

PL205497A1|1979-06-04|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3332950A|1963-03-23|1967-07-25|Endo Lab|14-hydroxydihydronormorphinone derivatives|

---

IL26896A|1966-01-19|1970-11-30|Endo Lab|14-hydroxynormorphines and 14-hydroxynormorphinones|

---

BE788478A|1971-09-08|1973-03-06|Bristol Myers Co|PROCESS FOR PREPARING ANALGESIC COMPOUNDS|

---

US4017497A|1975-11-18|1977-04-12|Bristol-Myers Company|Process for the preparation of 14-hydroxymorphinan derivatives|US4362870A|1980-01-16|1982-12-07|Regents Of The University Of Minnesota|Selective opioid receptor alkylating agents|

---

US4401672A|1981-10-13|1983-08-30|Regents Of The University Of Minnesota|Non-addictive narcotic antitussive preparation|

---

DE3381877D1|1982-03-16|1990-10-18|Univ Rockefeller|USE OF OPIUM ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE REMEDY OF GASTRO-INTESTINAL DISORDERS.|

---

GB8711558D0|1987-05-15|1987-06-17|Reckitt & Colmann Prod Ltd|Derivative of codeine|

---

JP2525552B2|1992-01-23|1996-08-21|東レ株式会社|Morphine derivative and pharmaceutical use|

---

JP3948026B2|1993-07-19|2007-07-25|東レ株式会社|Brain cell protectant|

---

JP3843456B2|1993-07-23|2006-11-08|東レ株式会社|Morphinan derivatives and pharmaceutical applications|

---

US20060063792A1|2004-09-17|2006-03-23|Adolor Corporation|Substituted morphinans and methods of their use|

---

ES2357216T3|2005-06-16|2011-04-20|Mallinckrodt, Inc.|A SYNTHESIS ROUTE OF 14-HYDROXYL-OPIACES THROUGH 1-HALO-THEBAINE OR ANALOGS.|

---

ES2784690T3|2013-12-05|2020-09-29|Univ Bath|New opioid compounds and their uses|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB12342/77A|GB1587831A|1977-03-23|1977-03-23|Morphine derivatives|

---